YAF2

Summary

YAF2 (YY1 associated factor 2, HGNC:17363) is a protein-coding gene on chromosome 12q12, encoding YY1-associated factor 2 (Q8IY57). Binds to MYC and inhibits MYC-mediated transactivation.

This gene encodes a zinc finger containing protein that functions in the regulation of transcription. This protein was identified as an interacting partner of transcriptional repressor protein Yy1, and also interacts with other transcriptional regulators, including Myc and Polycomb. This protein can promote proteolysis of Yy1. Multiple alternatively spliced transcript variants have been found.

Source: NCBI Gene 10138 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 31 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_005748

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17363
Approved symbol	YAF2
Name	YY1 associated factor 2
Location	12q12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000015153
Ensembl biotype	protein_coding
OMIM	607534
Entrez	10138

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 7 nonsense_mediated_decay, 6 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined

ENST00000327791, ENST00000380790, ENST00000534854, ENST00000541702, ENST00000546726, ENST00000546782, ENST00000546972, ENST00000547254, ENST00000547351, ENST00000547622, ENST00000547724, ENST00000548661, ENST00000548917, ENST00000550315, ENST00000551268, ENST00000551528, ENST00000552109, ENST00000552928, ENST00000555248, ENST00000880607

RefSeq mRNA: 5 — MANE Select: NM_005748 NM_001190977, NM_001190979, NM_001190980, NM_001320080, NM_005748

CCDS: CCDS31775, CCDS53778, CCDS53779, CCDS53780

Canonical transcript exons

ENST00000534854 — 4 exons

Exon	Start	End
ENSE00001328312	42157104	42160826
ENSE00003483672	42238155	42238248
ENSE00003524511	42237599	42237724
ENSE00003572403	42161613	42161765

Expression profiles

Bgee: expression breadth ubiquitous, 203 present calls, max score 92.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.2914 / max 265.9175, expressed in 1793 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130481	9.4437	1745
130483	5.1806	1621
130482	0.8561	589
130480	0.4595	201
130479	0.3515	171

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right atrium auricular region	UBERON:0006631	92.61	gold quality
calcaneal tendon	UBERON:0003701	92.49	gold quality
gastrocnemius	UBERON:0001388	91.63	gold quality
colonic epithelium	UBERON:0000397	91.26	gold quality
muscle of leg	UBERON:0001383	91.21	gold quality
heart left ventricle	UBERON:0002084	90.80	gold quality
cardiac ventricle	UBERON:0002082	90.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.22	gold quality
ventricular zone	UBERON:0003053	90.19	gold quality
sural nerve	UBERON:0015488	89.47	gold quality
cortical plate	UBERON:0005343	89.35	gold quality
cardiac atrium	UBERON:0002081	89.29	gold quality
ganglionic eminence	UBERON:0004023	89.23	gold quality
heart	UBERON:0000948	89.12	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.62	gold quality
stromal cell of endometrium	CL:0002255	88.24	gold quality
left lobe of thyroid gland	UBERON:0001120	88.04	gold quality
monocyte	CL:0000576	87.76	gold quality
prefrontal cortex	UBERON:0000451	87.75	gold quality
tibial artery	UBERON:0007610	87.48	gold quality
popliteal artery	UBERON:0002250	87.47	gold quality
mononuclear cell	CL:0000842	87.36	gold quality
leukocyte	CL:0000738	87.31	gold quality
right lobe of thyroid gland	UBERON:0001119	87.31	gold quality
endocervix	UBERON:0000458	86.79	gold quality
aorta	UBERON:0000947	86.57	gold quality
adrenal tissue	UBERON:0018303	86.24	gold quality
thyroid gland	UBERON:0002046	86.04	gold quality
ectocervix	UBERON:0012249	85.94	gold quality
thoracic aorta	UBERON:0001515	85.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

138 targeting YAF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-335-3P	99.93	73.36	4958

Literature-anchored findings (GeneRIF, showing 5)

• YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors. (PMID:11953439)
• These findings uncovered an apoptotic signaling cascade linking YAF2, PDCD5, and TP53 during genotoxic stress responses. (PMID:25603536)
• LINC00341 interacts with miR-141 to suppress its functional binding to the 3’-untranslated region of YAF2 messenger RNA whereby supporting chondrocyte survival and preventing osteoarthritis progression. (PMID:30672021)
• miR-34b inhibits the migration/invasion and promotes apoptosis of non-small-cell lung cancer cells by YAF2. (PMID:30915747)
• YAF2 exerts anti-apoptotic effect in human tumor cells in a FANK1- and phosphorylation-dependent manner. (PMID:33784512)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	yaf2	ENSDARG00000015966
mus_musculus	Yaf2	ENSMUSG00000022634
rattus_norvegicus	Yaf2	ENSRNOG00000004773
drosophila_melanogaster	RYBP	FBGN0034763
caenorhabditis_elegans		WBGENE00016937

Paralogs (1): RYBP (ENSG00000163602)

Protein

Protein identifiers

YY1-associated factor 2 — Q8IY57 (reviewed: Q8IY57)

All UniProt accessions (8): Q8IY57, A0A0B4J255, F8VRE5, F8VZR2, F8W0B9, G3V1X5, G3V212, G3V219

UniProt curated annotations — full annotation on UniProt →

Function. Binds to MYC and inhibits MYC-mediated transactivation. Also binds to MYCN and enhances MYCN-dependent transcriptional activation. Increases calpain 2-mediated proteolysis of YY1 in vitro. Component of the E2F6.com-1 complex, a repressive complex that methylates ‘Lys-9’ of histone H3, suggesting that it is involved in chromatin-remodeling.

Subunit / interactions. Interacts with MYC, MYCN, RNF2/RING1B and YY1. Part of the E2F6.com-1 complex in G0 phase composed of E2F6, MGA, MAX, TFDP1, CBX3, BAT8, EUHMTASE1, RING1, RNF2, MBLR, L3MBTL2 and YAF2.

Subcellular location. Nucleus.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8IY57-1	1	yes
Q8IY57-5	2
Q8IY57-3	3
Q8IY57-4	4

RefSeq proteins (5): NP_001177906, NP_001177908, NP_001177909, NP_001307009, NP_005739* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001876	Znf_RanBP2	Domain
IPR033774	YAF2_RYBP	Conserved_site
IPR036443	Znf_RanBP2_sf	Homologous_superfamily
IPR039958	RYBP/YAF2	Family

Pfam: PF00641, PF17219

UniProt features (18 total): compositionally biased region 5, splice variant 4, region of interest 3, strand 2, chain 1, zinc finger region 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2D9G	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IY57-F1	68.38	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 167

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
R-HSA-8953750	Transcriptional Regulation by E2F6

MSigDB gene sets: 205 (showing top): BENPORATH_ES_WITH_H3K27ME3, MORF_MSH3, XU_GH1_AUTOCRINE_TARGETS_UP, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MORF_BRCA1, MORF_ATRX, chr12q12, BROWNE_HCMV_INFECTION_16HR_UP, ATGCAGT_MIR217, PUJANA_CHEK2_PCC_NETWORK, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, CAGCAGG_MIR370, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN, GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN

GO Biological Process (3): regulation of DNA-templated transcription (GO:0006355), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (7): DNA binding (GO:0003677), transcription coregulator activity (GO:0003712), transcription coactivator activity (GO:0003713), transcription corepressor activity (GO:0003714), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Transcriptional regulation by RUNX1	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	3
regulation of DNA-templated transcription	2
transcription coregulator activity	2
cellular anatomical structure	2
regulation of gene expression	1
regulation of RNA biosynthetic process	1
negative regulation of RNA biosynthetic process	1
positive regulation of RNA biosynthetic process	1
nucleic acid binding	1
transcription regulator activity	1
positive regulation of DNA-templated transcription	1
negative regulation of DNA-templated transcription	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1

Protein interactions and networks

STRING

584 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YAF2	RING1	Q06587	998
YAF2	PCGF1	Q9BSM1	995
YAF2	RNF2	Q99496	992
YAF2	PCGF6	Q9BYE7	977
YAF2	YY1	P25490	971
YAF2	KDM2B	Q8NHM5	965
YAF2	RYBP	Q8N488	948
YAF2	PCGF3	Q3KNV8	903
YAF2	PCGF2	P35227	897
YAF2	CBX2	Q14781	883
YAF2	GABPB1	Q06547	864
YAF2	PCGF5	Q86SE9	862
YAF2	SKP1	P34991	823
YAF2	BMI1	P35226	799
YAF2	R4GMX3	R4GMX3	799

IntAct

88 interactions, top by confidence:

A	B	Type	Score
BMI1	CBX4	psi-mi:“MI:0914”(association)	0.900
YAF2	RING1	psi-mi:“MI:0915”(physical association)	0.880
RING1	YAF2	psi-mi:“MI:0915”(physical association)	0.880
PCGF5	CSNK2A2	psi-mi:“MI:0914”(association)	0.880
PCGF2	CBX4	psi-mi:“MI:0914”(association)	0.840
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
RING1	CBX4	psi-mi:“MI:0914”(association)	0.730
RNF2	E2F6	psi-mi:“MI:0914”(association)	0.730
DCAF7	DIAPH1	psi-mi:“MI:0914”(association)	0.730
L3MBTL2	E2F6	psi-mi:“MI:0914”(association)	0.730
MAX	E2F6	psi-mi:“MI:0914”(association)	0.710
WDR5	MEN1	psi-mi:“MI:0914”(association)	0.710
XAGE1A	YAF2	psi-mi:“MI:0915”(physical association)	0.670
RNF2	CBX4	psi-mi:“MI:0914”(association)	0.660
YAF2	E2F6	psi-mi:“MI:0914”(association)	0.640
P4HA3	FAM171A2	psi-mi:“MI:0914”(association)	0.640
YAF2	YY1	psi-mi:“MI:0915”(physical association)	0.590
YY1	YAF2	psi-mi:“MI:0407”(direct interaction)	0.590

BioGRID (384): YAF2 (Two-hybrid), YAF2 (Two-hybrid), SETBP1 (Two-hybrid), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), RING1 (Two-hybrid), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS), YAF2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I6G705, A1L3K1, B5DFF2, B5DFI8, G3MWR8, O19048, O19137, O88508, P06730, P29338, P57721, P57722, P60335, Q12800, Q13888, Q15365, Q15366, Q16763, Q1LZ53, Q1RML1, Q28D01, Q2TBV5, Q4W5Z4, Q5E9A3, Q5FVR7, Q5NVP9, Q5TDH0, Q61990, Q6AYU1, Q6DH13, Q6P1K8, Q6ZRY4, Q7RTP6, Q8C6G8, Q8CCI5, Q8CJ19, Q8IY57, Q8N488, Q8VC52, Q921J4

Diamond homologs: Q5EG55, Q7SYB3, Q8CCI5, Q8IY57, Q8N488, Q99LW6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 87 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of DNA methylation proteins	5	58.9×	1e-06
Transcriptional Regulation by E2F6	9	46.2×	5e-11
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	8	42.2×	1e-09
SUMOylation of transcription cofactors	5	21.3×	1e-04
SUMOylation of RNA binding proteins	5	20.9×	1e-04
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	8	20.6×	4e-07
SUMOylation of chromatin organization proteins	6	16.7×	8e-05
Regulation of PTEN gene transcription	5	15.7×	5e-04

GO biological processes:

GO term	Partners	Fold	FDR
anatomical structure morphogenesis	7	12.8×	2e-04
chromatin remodeling	13	12.5×	1e-08
transcription by RNA polymerase II	7	6.5×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	22
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1048618	GRCh37/hg19 12q11-13.12(chr12:37873948-49578619)x3	Likely pathogenic

SpliceAI

1895 predictions. Top by Δscore:

Variant	Effect	Δscore
12:42160827:C:CC	acceptor_gain	1.0000
12:42161608:TTTAC:T	donor_loss	1.0000
12:42161609:TTA:T	donor_loss	1.0000
12:42161610:TA:T	donor_loss	1.0000
12:42161612:C:CA	donor_loss	1.0000
12:42161761:GTTTC:G	acceptor_gain	1.0000
12:42161763:TTC:T	acceptor_gain	1.0000
12:42161764:TC:T	acceptor_gain	1.0000
12:42161764:TCC:T	acceptor_loss	1.0000
12:42161765:CCTG:C	acceptor_gain	1.0000
12:42161766:C:CC	acceptor_gain	1.0000
12:42161768:G:C	acceptor_gain	1.0000
12:42161768:G:GC	acceptor_gain	1.0000
12:42161770:G:C	acceptor_gain	1.0000
12:42161770:G:GC	acceptor_gain	1.0000
12:42161773:C:CT	acceptor_gain	1.0000
12:42161774:A:AC	acceptor_gain	1.0000
12:42161774:A:C	acceptor_gain	1.0000
12:42161776:G:C	acceptor_gain	1.0000
12:42161776:G:GC	acceptor_gain	1.0000
12:42161777:T:C	acceptor_gain	1.0000
12:42161777:T:TC	acceptor_gain	1.0000
12:42210543:CTTA:C	donor_loss	1.0000
12:42210544:TTACC:T	donor_loss	1.0000
12:42210545:TA:T	donor_loss	1.0000
12:42210546:ACCTT:A	donor_gain	1.0000
12:42210547:CCTTC:C	donor_gain	1.0000
12:42210550:T:A	donor_gain	1.0000
12:42210685:C:CT	acceptor_gain	1.0000
12:42238150:GTTAC:G	donor_loss	1.0000

AlphaMissense

1182 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:42160742:A:C	F130L	1.000
12:42160742:A:T	F130L	1.000
12:42160743:A:G	F130S	1.000
12:42160744:A:G	F130L	1.000
12:42160752:A:C	I127S	1.000
12:42160752:A:G	I127T	1.000
12:42160752:A:T	I127N	1.000
12:42160758:A:T	V125D	1.000
12:42160764:A:G	L123P	1.000
12:42160779:A:T	V118D	1.000
12:42160818:A:G	L105S	1.000
12:42161762:T:A	K52N	1.000
12:42161762:T:G	K52N	1.000
12:42161764:T:C	K52E	1.000
12:42237602:G:A	T50I	1.000
12:42237605:G:A	S49F	1.000
12:42237605:G:T	S49Y	1.000
12:42237608:G:A	T48I	1.000
12:42237611:C:A	G47V	1.000
12:42237611:C:T	G47D	1.000
12:42237612:C:A	G47C	1.000
12:42237612:C:G	G47R	1.000
12:42237612:C:T	G47S	1.000
12:42237613:C:A	K46N	1.000
12:42237613:C:G	K46N	1.000
12:42237614:T:A	K46M	1.000
12:42237614:T:G	K46T	1.000
12:42237615:T:C	K46E	1.000
12:42237615:T:G	K46Q	1.000
12:42237625:G:C	C42W	1.000

dbSNP variants (sampled 300 via entrez): RS1000032843 (12:42210093 C>G,T), RS1000126663 (12:42167864 C>T), RS1000183378 (12:42215894 C>A,G,T), RS1000186416 (12:42225198 C>T), RS1000187627 (12:42173856 T>C), RS1000192547 (12:42218471 ATTG>A), RS1000228968 (12:42198898 A>T), RS1000263244 (12:42161558 A>C), RS1000347459 (12:42224557 G>A,T), RS1000357006 (12:42180985 C>A,T), RS1000371485 (12:42180686 C>G,T), RS1000425295 (12:42180424 T>C), RS1000457366 (12:42232199 GT>G), RS1000496459 (12:42238974 G>A,T), RS1000552563 (12:42210363 T>G)

Disease associations

OMIM: gene MIM:607534 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_215	Refractive error	3.000000e-11

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6193827 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, decreases expression, increases abundance	2
Benzo(a)pyrene	increases methylation, increases expression	2
FR900359	affects phosphorylation	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
sodium arsenite	increases abundance, increases expression, affects cotreatment	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, decreases expression	1
Irinotecan	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Acetaldehyde	increases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Caffeine	increases phosphorylation	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, decreases expression	1
Coal	decreases expression, increases abundance	1
Dietary Carbohydrates	decreases expression	1
Doxorubicin	decreases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Ozone	decreases expression, increases abundance, affects cotreatment	1
Phenobarbital	affects expression	1
Plant Extracts	affects cotreatment, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5548053	Binding	PROTAC activity at CRBN/YAF in human K562 cells assessed as degradation of YAF protein expression at 1 to 10 uM incubated for 24 hrs by Western blotting analysis	Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.